好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Evaluation of Neuromuscular Patient Perspective on Telehealth Amid COVID-19 Pandemic
Practice, Policy, and Ethics
Practice, Policy, and Ethics Posters (7:00 AM-5:00 PM)
019

Determine neuromuscular patient satisfaction (established patients only) of telehealth as the prevalence of virtual appointments rise during COVID-19 pandemic.

There are limited data on telehealth satisfaction among patients with neuromuscular diseases except for amyotrophic lateral sclerosis (ALS).

Patients completed a telehealth satisfaction survey during tele-medicine clinic for return visits and rated eight aspects from 1 (strongly disagree) to 5 (strongly agree): Communication, timeliness of physician, picture quality, sound quality, protection of privacy, comfort of physical exam, ease of healthcare, and whether patients would prefer “in-person” visits despite safety precaution. We received 50 surveys from a cohort of 90. We performed one-sample T-tests for each survey component and compared responses to a value of “3” corresponding to “neutral”. After averaging individual survey responses, we performed independent T-tests and ANOVA to determine the relationship of demographic factors to average satisfaction ratings.

Average age was 47.54 ± 20.63, M:F ratio of 23:27, rural to urban ratio of 35:15, and 30 of 50 patients had family present webside while 7 of 50 had family present remotely. 44 out of 50 patients were Caucasian, while four were African-American and two were Hispanic. All patients responded to each survey component with mean score of  >4 (p < 0.05) with the exception of whether patients preferred in-person appointments (2.66 ± 0.63) which shows patients do not prefer in-person appointments.

Further analysis reveals there was no significant effect for gender, location, family present webside/remotely, ethnicity, or age (p > 0.05). The top three diagnoses include myasthenia gravis (4.54 ± 0.57), ALS (4.06 ± 0.26), and Charcot-Marie-Tooth type 1A (4.07 ± 0.71). There was no significant effect of diagnosis on average satisfaction ratings [F(19,28) = 1.97, p = 0.051].

Patients are satisfied with telehealth regardless of demographics. Future studies with larger sample sizes are required to confirm our results.

Authors/Disclosures
Junsang Cho
PRESENTER
Mr. Cho has nothing to disclose.
Sara Hooshmand, MD (Mayo Clinic) Dr. Hooshmand has nothing to disclose.
Shivangi Singh, MD (Columbia Neurology) Miss Singh has nothing to disclose.
Raghav Govindarajan, MD, FAAN (HSHS St. Elizabeth Medical Group) Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for MT pharma. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Catalyst. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amicus. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for MT pharma . Dr. Govindarajan has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Catalyst. Dr. Govindarajan has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Biohaven. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Govindarajan has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Govindarajan has received research support from Band of Hope . The institution of Dr. Govindarajan has received research support from Alexion. Dr. Govindarajan has received publishing royalties from a publication relating to health care.